Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciardiello, F.
Right arrow Articles by Tortora, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciardiello, F.
Right arrow Articles by Tortora, G.
Clinical Cancer Research Vol. 6, 2053-2063, May 2000
© 2000 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor1

Fortunato Ciardiello2, Rosa Caputo, Roberto Bianco, Vincenzo Damiano, Grazia Pomatico, Sabino De Placido, A. Raffaele Bianco and Giampaolo Tortora

Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi di Napoli Federico II, 5-80131 Naples, Italy

Transforming growth factor {alpha} (TGF-{alpha}) is an autocrine growth factor for human cancer. Overexpression of TGF-{alpha} and its specific receptor, the epidermal growth factor receptor (EGFR), is associated with aggressive disease and poor prognosis. The EGFR has been proposed as a target for anticancer therapy. Compounds that block ligand-induced EGFR activation have been developed. ZD-1839 (Iressa) is a p.o.-active, quinazoline derivative that selectively inhibits the EGFR tyrosine kinase and is under clinical development in cancer patients. The antiproliferative activity of ZD-1839 alone or in combination with cytotoxic drugs differing in mechanism(s) of action, such as cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, doxorubicin, etoposide, topotecan, and raltitrexed, was evaluated in human ovarian (OVCAR-3), breast (ZR-75–1, MCF-10A ras), and colon cancer (GEO) cells that coexpress EGFR and TGF-{alpha}. ZD-1839 inhibited colony formation in soft agar in a dose-dependent manner in all cancer cell lines. The antiproliferative effect was mainly cytostatic. However, treatment with higher doses resulted in a 2–4-fold increase in apoptosis. A dose-dependent supra-additive increase in growth inhibition was observed when cancer cells were treated with each cytotoxic drug and ZD-1839. The combined treatment markedly enhanced apoptotic cell death induced by single-agent treatment. ZD-1839 treatment of nude mice bearing established human GEO colon cancer xenografts revealed a reversible dose-dependent inhibition of tumor growth because GEO tumors resumed the growth rate of controls at the end of the treatment. In contrast, the combined treatment with a cytotoxic agent, such as topotecan, raltitrexed, or paclitaxel, and ZD-1839 produced tumor growth arrest in all mice. Tumors grew slowly for approximately 4–8 weeks after the end of treatment, when they finally resumed a growth rate similar to controls. GEO tumors reached a size not compatible with normal life in all control mice within 4–6 weeks and in all single agent-treated mice within 6–8 weeks after GEO cell injection. In contrast, 50% of mice treated with ZD-1839 plus topotecan, raltitrexed, or paclitaxel were still alive 10, 12, and 15 weeks after cancer cell injection, respectively. These results demonstrate the antitumor effect of this EGFR-selective tyrosine kinase inhibitor and provide a rationale for its clinical evaluation in combination with cytotoxic drugs.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
G. Vlotides, E. Siegel, I. Donangelo, S. Gutman, S.-G. Ren, and S. Melmed
Rat Prolactinoma Cell Growth Regulation by Epidermal Growth Factor Receptor Ligands
Cancer Res., August 1, 2008; 68(15): 6377 - 6386.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J.-C. Ko, S.-C. Ciou, C.-M. Cheng, L.-H. Wang, J.-H. Hong, M.-Y. Jheng, S.-T. Ling, and Y.-W. Lin
Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells
Carcinogenesis, July 1, 2008; 29(7): 1448 - 1458.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Kelly, K. Chansky, L. E. Gaspar, K. S. Albain, J. Jett, Y. C. Ung, D. H.M. Lau, J. J. Crowley, and D. R. Gandara
Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non-Small-Cell Lung Cancer: SWOG S0023
J. Clin. Oncol., May 20, 2008; 26(15): 2450 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
E. C. Brantley and E. N. Benveniste
Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas
Mol. Cancer Res., May 1, 2008; 6(5): 675 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Ren, B. Korchin, Q.-S. Zhu, C. Wei, A. Dicker, J. Heymach, A. Lazar, R. E. Pollock, and D. Lev
Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo
Clin. Cancer Res., May 1, 2008; 14(9): 2785 - 2795.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Q. Wei, L. Sheng, Y. Shui, Q. Hu, H. Nordgren, and J. Carlsson
EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases
Ann. Surg. Oncol., April 1, 2008; 15(4): 1193 - 1201.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. M. Thomas, M. J. Ogagan, M. L. Freilino, S. Strychor, D. R. Walsh, W. E. Gooding, J. R. Grandis, and W. C. Zamboni
Antitumor Mechanisms of Systemically Administered Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck
Mol. Pharmacol., March 1, 2008; 73(3): 627 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Cavazzoni, R. R. Alfieri, C. Carmi, V. Zuliani, M. Galetti, C. Fumarola, R. Frazzi, M. Bonelli, F. Bordi, A. Lodola, et al.
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines
Mol. Cancer Ther., February 1, 2008; 7(2): 361 - 370.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Wang, P. Guo, X. Wang, Q. Zhou, and J. M. Gallo
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
Mol. Cancer Ther., February 1, 2008; 7(2): 407 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Pattarozzi, M. Gatti, F. Barbieri, R. Wurth, C. Porcile, G. Lunardi, A. Ratto, R. Favoni, A. Bajetto, A. Ferrari, et al.
17 -Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment
Mol. Pharmacol., January 1, 2008; 73(1): 191 - 202.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Chen, M. Kane, J. Song, J. Campana, A. Raben, K. Hu, L. Harrison, H. Quon, J. Dancey, A. Baron, et al.
Phase I Trial of Gefitinib in Combination With Radiation or Chemoradiation for Patients With Locally Advanced Squamous Cell Head and Neck Cancer
J. Clin. Oncol., November 1, 2007; 25(31): 4880 - 4886.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Aschele and S. Lonardi
Multidisciplinary treatment of rectal cancer: medical oncology.
Ann. Onc., November 1, 2007; 18(11): 1908 - 1915.
[Full Text] [PDF]

Home page
 J Biomol ScreenHome page
S. N. Anderson, D. L. Towne, D. J. Burns, and U. Warrior
A High-Throughput Soft Agar Assay for Identification of Anticancer Compound
J Biomol Screen, October 1, 2007; 12(7): 938 - 945.
[Abstract] [PDF]

Home page
 JCOHome page
P. M. Harari, G. W. Allen, and J. A. Bonner
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
J. Clin. Oncol., September 10, 2007; 25(26): 4057 - 4065.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Taylor, D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, et al.
Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Clin. Cancer Res., September 1, 2007; 13(17): 5133 - 5143.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. D. Bonomi, L. Buckingham, and J. Coon
Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Clin. Cancer Res., August 1, 2007; 13(15): 4606s - 4612s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. P. Piechocki, G. H. Yoo, S. K. Dibbley, and F. Lonardo
Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib In vitro and In vivo and Acquires Resistance through a Novel Point Mutation in the HER2/neu
Cancer Res., July 15, 2007; 67(14): 6825 - 6843.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Cruz, A Ocana, E Del Barco, and A Pandiella
Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
Ann. Onc., March 1, 2007; 18(3): 421 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Shrader, M. S. Pino, L. Lashinger, M. Bar-Eli, L. Adam, C. P.N. Dinney, and D. J. McConkey
Gefitinib Reverses TRAIL Resistance in Human Bladder Cancer Cell Lines via Inhibition of AKT-Mediated X-Linked Inhibitor of Apoptosis Protein Expression
Cancer Res., February 15, 2007; 67(4): 1430 - 1435.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. V. Sequist, D. W. Bell, T. J. Lynch, and D. A. Haber
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 10, 2007; 25(5): 587 - 595.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. K. Gan, F. Walker, A. W. Burgess, A. Rigopoulos, A. M. Scott, and T. G. Johns
The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers: IMPLICATIONS FOR COMBINATION THERAPY WITH MONOCLONAL ANTIBODY 806
J. Biol. Chem., February 2, 2007; 282(5): 2840 - 2850.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Fichera, N. Little, S. Jagadeeswaran, U. Dougherty, A. Sehdev, R. Mustafi, S. Cerda, W. Yuan, S. Khare, M. Tretiakova, et al.
Epidermal Growth Factor Receptor Signaling Is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis
Cancer Res., January 15, 2007; 67(2): 827 - 835.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Shrader, M. S. Pino, G. Brown, P. Black, L. Adam, M. Bar-Eli, C. P.N. Dinney, and D. J. McConkey
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 277 - 285.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. P. Mitra, R. H. Datar, and R. J. Cote
Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification
J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H. E Jones, J. M W Gee, I. R Hutcheson, J. M Knowlden, D. Barrow, and R. I Nicholson
Growth factor receptor interplay and resistance in cancer
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S45 - S51.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
I. R Hutcheson, J. M Knowlden, H. E Jones, R. S Burmi, R. A McClelland, D. Barrow, J. M W Gee, and R. I Nicholson
Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S89 - S97.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. N. Younes, Y. W. Park, Y. D. Yazici, M. Gu, A. A. Santillan, X. Nong, S. Kim, S. A. Jasser, A. K. El-Naggar, and J. N. Myers
Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Mol. Cancer Ther., November 1, 2006; 5(11): 2696 - 2705.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. H. Johnson
Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-i. Ueda, Y. Basaki, M. Yoshie, K. Ogawa, S. Sakisaka, M. Kuwano, and M. Ono
PTEN/Akt Signaling through Epidermal Growth Factor Receptor Is Prerequisite for Angiogenesis by Hepatocellular Carcinoma Cells That Is Susceptible to Inhibition by Gefitinib.
Cancer Res., May 15, 2006; 66(10): 5346 - 5353.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Sato, M. B. Vaughan, L. Girard, M. Peyton, W. Lee, D. S. Shames, R. D. Ramirez, N. Sunaga, A. F. Gazdar, J. W. Shay, et al.
Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells
Cancer Res., February 15, 2006; 66(4): 2116 - 2128.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. G. Czito, C. G. Willett, J. C. Bendell, M. A. Morse, D. S. Tyler, N. H. Fernando, C. R. Mantyh, G. C. Blobe, W. Honeycutt, D. Yu, et al.
Increased Toxicity With Gefitinib, Capecitabine, and Radiation Therapy in Pancreatic and Rectal Cancer: Phase I Trial Results
J. Clin. Oncol., February 1, 2006; 24(4): 656 - 662.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. J. Friedmann, M. Caplin, B. Savic, T. Shah, C. J. Lord, A. Ashworth, J. A. Hartley, and D. Hochhauser
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
Mol. Cancer Ther., February 1, 2006; 5(2): 209 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Y. Chun, F. Y. Feng, A. M. Scheurer, M. A. Davis, T. S. Lawrence, and M. K. Nyati
Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma
Cancer Res., January 15, 2006; 66(2): 981 - 988.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
M. D. Prados, K. R. Lamborn, S. Chang, E. Burton, N. Butowski, M. Malec, A. Kapadia, J. Rabbitt, M. S. Page, A. Fedoroff, et al.
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
Neuro-oncol, January 1, 2006; 8(1): 67 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Zhou, S. Li, Y. P. Hu, J. Wang, J. Hauser, A. N. Conway, M. A. Vinci, L. Humphrey, E. Zborowska, J. K.V. Willson, et al.
Blockade of EGFR and ErbB2 by the Novel Dual EGFR and ErbB2 Tyrosine Kinase Inhibitor GW572016 Sensitizes Human Colon Carcinoma GEO Cells to Apoptosis
Cancer Res., January 1, 2006; 66(1): 404 - 411.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C Festuccia, P Muzi, D Millimaggi, L Biordi, G L Gravina, S Speca, A Angelucci, V Dolo, C Vicentini, and M Bologna
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines
Endocr. Relat. Cancer, December 1, 2005; 12(4): 983 - 998.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Gasparini, R. Sarmiento, S. Amici, R. Longo, D. Gattuso, M. Zancan, and M. Gion
Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate
Ann. Onc., December 1, 2005; 16(12): 1867 - 1873.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Kassouf, C. P.N. Dinney, G. Brown, D. J. McConkey, A. J. Diehl, M. Bar-Eli, and L. Adam
Uncoupling between Epidermal Growth Factor Receptor and Downstream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells
Cancer Res., November 15, 2005; 65(22): 10524 - 10535.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Liu, H. Li, M. Derouet, J. Filmus, E. C. LaCasse, R. G. Korneluk, R. S. Kerbel, and K. V. Rosen
ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells: EPIDERMAL GROWTH FACTOR RECEPTOR-DEPENDENT AND -INDEPENDENT MECHANISMS OF ras-INDUCED TRANSFORMATION
J. Biol. Chem., November 11, 2005; 280(45): 37383 - 37392.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Tabernero, T. Macarulla, F. J. Ramos, and J. Baselga
Novel targeted therapies in the treatment of gastric and esophageal cancer
Ann. Onc., November 1, 2005; 16(11): 1740 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Van Schaeybroeck, A. Karaiskou-McCaul, D. Kelly, D. Longley, L. Galligan, E. Van Cutsem, and P. Johnston
Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy
Clin. Cancer Res., October 15, 2005; 11(20): 7480 - 7489.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. C. Daw, W. L. Furman, C. F. Stewart, L. C. Iacono, M. Krailo, M. L. Bernstein, J. E. Dancey, R. A. Speights, S. M. Blaney, J. M. Croop, et al.
Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol., September 1, 2005; 23(25): 6172 - 6180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, Z. Chen, M. S. Choe, Y. Lin, S.-Y. Sun, H. S. Wieand, H. J. C. Shin, A. Chen, F. R. Khuri, and D. M. Shin
Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model
Clin. Cancer Res., September 1, 2005; 11(17): 6261 - 6269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Kuo, C. D. Cho, J. Halsey, H. A. Wakelee, R. H. Advani, J. M. Ford, G. A. Fisher, and B. I. Sikic
Phase II Study of Gefitinib, Fluorouracil, Leucovorin, and Oxaliplatin Therapy in Previously Treated Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., August 20, 2005; 23(24): 5613 - 5619.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. A. Burris III, H. I. Hurwitz, E. C. Dees, A. Dowlati, K. L. Blackwell, B. O'Neil, P. K. Marcom, M. J. Ellis, B. Overmoyer, S. F. Jones, et al.
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
J. Clin. Oncol., August 10, 2005; 23(23): 5305 - 5313.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Cappuzzo, M. Varella-Garcia, H. Shigematsu, I. Domenichini, S. Bartolini, G. L. Ceresoli, E. Rossi, V. Ludovini, V. Gregorc, L. Toschi, et al.
Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients
J. Clin. Oncol., August 1, 2005; 23(22): 5007 - 5018.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-H. Yang, C.-J. Huang, C.-S. Yang, Y.-C. Chu, A.-L. Cheng, J. Whang-Peng, and P.-C. Yang
Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein
Cancer Res., August 1, 2005; 65(15): 6943 - 6949.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Schilder, M. W. Sill, X. Chen, K. M. Darcy, S. L. Decesare, G. Lewandowski, R. B. Lee, C. A. Arciero, H. Wu, and A. K. Godwin
Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
Clin. Cancer Res., August 1, 2005; 11(15): 5539 - 5548.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kiguchi, L. Ruffino, T. Kawamoto, T. Ajiki, and J. DiGiovanni
Chemopreventive and Therapeutic Efficacy of Orally Active Tyrosine Kinase Inhibitors in a Transgenic Mouse Model of Gallbladder Carcinoma
Clin. Cancer Res., August 1, 2005; 11(15): 5572 - 5580.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Terry, J. M. Lubieniecka, W. Kwan, S. Liu, and T. O. Nielsen
Hsp90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Prevents Synovial Sarcoma Proliferation via Apoptosis in In vitro Models
Clin. Cancer Res., August 1, 2005; 11(15): 5631 - 5638.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Friess, W. Scheuer, and M. Hasmann
Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy
Clin. Cancer Res., July 15, 2005; 11(14): 5300 - 5309.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Zhou and M. G. Brattain
Synergy of Epidermal Growth Factor Receptor Kinase Inhibitor AG1478 and ErbB2 Kinase Inhibitor AG879 in Human Colon Carcinoma Cells Is Associated with Induction of Apoptosis
Cancer Res., July 1, 2005; 65(13): 5848 - 5856.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H E Jones, J M W Gee, K M Taylor, D Barrow, H D Williams, M Rubini, and R I Nicholson
Development of strategies for the use of anti-growth factor treatments
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S173 - S182.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Xia, S. R. Kumar, R. Masood, M. Koss, C. Templeman, D. Quinn, S. Zhu, R. Reddy, V. Krasnoperov, and P. S. Gill
Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance
Clin. Cancer Res., June 15, 2005; 11(12): 4305 - 4315.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Hirata, F. Hosoi, M. Miyagawa, S.-i. Ueda, S. Naito, T. Fujii, M. Kuwano, and M. Ono
HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells
Cancer Res., May 15, 2005; 65(10): 4253 - 4260.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. Yoshimoto, K. Kasahara, M. Nishio, T. Hourai, T. Sone, H. Kimura, M. Fujimura, and S. Nakao
Changes in Angiogenic Growth Factor Levels After Gefitinib Treatment in Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 233 - 238.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Jimeno, B. Rubio-Viqueira, M. L. Amador, D. Oppenheimer, N. Bouraoud, P. Kulesza, V. Sebastiani, A. Maitra, and M. Hidalgo
Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents
Cancer Res., April 15, 2005; 65(8): 3003 - 3010.
[Abstract] [Full Text] [PDF]